The Re-Emerging Role of Iron in Infection and Immunity

Mawieh Hamad1,2* and Khuloud Bajbouj2
1Department of Medical Laboratory Sciences
2Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE

Abstract
Much has been achieved over the past three decades in the quest to understand iron homeostasis and the mechanisms governing it. Several proteins including hepcidin, ferroprtin, transferrin receptors, and ferritin have been identified as key players in iron metabolism and homeostasis. This has provided for a thorough revisiting of the role of iron in various disease states including cancer, cardiovascular diseases, and susceptibility to infection to name few. Regarding the later, although the idea that iron is essential for microbial pathogenesis has been known for a long time, knowledge regarding key mechanisms employed by pathogens to extract iron and counter mechanisms employed by the immune system to sequester iron has expanded in a significant way. Furthermore, there is renewed interest in the role of iron in immunity and the extent and ramifications of the reciprocal effects of either on the other. This mini-review starts by introducing the reader to the basics of iron metabolism and goes on to briefly, but non-exhaustively, recount the epic fight for iron between pathogen and host.

Background
The discovery that iron regulates ferritin mRNA translation [1] and the subsequent identification of several key genes and proteins involved in iron metabolism has marked the start of a new age for iron biology. Owing to its unique electrochemical properties, iron functions as a redox active cofactor in a wide array of biological processes. Cellular and secreted enzymes and proteins that use iron as a cofactor are involved in all aspects of cell metabolism including cellular respiration, DNA replication, gene expression, cell cycling, cell signaling and apoptosis among others. Iron also serves as a sensor of cellular redox status; that is, iron-based sensors use iron-containing molecules (heme, Fe-S clusters, mononuclear iron, etc.) as switches to regulate protein activity in response to changes in cellular redox balance [2]. Hence, iron deficiency associates with a wide range of adverse health consequences including anemia and compromised immunity. Excess iron on the other hand, which under aerobic conditions drives the propagation and generation of oxygen and hydroxyl free radicals, associates with compromised immunity, cancer, cardiovascular disease, and inflammation among other disease states. Renewed interest in iron biology in recent years has deepened our understanding of how iron metabolism is regulated and has also provided for a more systematic approach to address the role of disrupted iron homeostasis in disease.

Iron homeostasis: the basics
Mammalian systems have evolved intricate mechanisms to maintain iron homeostasis and to tightly regulate iron absorption and release (Figure 1). Ferroportin (FPN) channels on enterocytes and macrophages efflux intracellular ferrous iron into the circulation, first to be instantaneously oxidized by ceruloplasmin and/or hephaestin and then loaded onto transferrin [3]. The ferric-transferrin complex is subsequently delivered to target cells by endocytosis through transferrin receptor 1 (TFR1; CD71). FPN expression is negatively impacted by the hepatocyte-derived peptide hormone hepcidin, which triggers the internalization, phosphorylation and degradation of FPN [4]. Increased demand for iron therefore downregulates hepcidin synthesis by upregulating the transcription of hypoxia inducible factor 1α (HIF-1α) [5] and the growth differentiation factor 15 (GDF15) [6] among other mechanism [7]. In contrast, ferric-transferrin complex in excess induces the disengagement of the human hemochomatosis (HFE) protein from TFR1 and its engagement with TFR2, an event that upregulates hepcidin synthesis [4,8]. Inflammatory cytokines (IL-6 and IL-1) [9,10] and innate immunity receptors (toll-like receptor 4; TLR-4) [11] can also upregulate hepcidin gene expression as means of intracellular iron sequestration during infection.

In addition to changing demand and inflammation, mounting evidence suggest that iron homeostasis can be influenced by estrogen...
dissemination [24]. To counter such an inflammation-dependent iron block intracellular iron efflux [22]. By doing so, innate immunity and IL-6 among other mediators that enhance hepcidin synthesis and upregulating FPN expression, E2 treatment was recently reported to upregulate hepcidin synthesis [21]. By downregulating hepcidin TGF-β1, and TLR5, at least some of which (IL-1 and IL-6) are known to inhibit the release of several cytokines including IL-1, IL-6, IL-22, hence its role in intracellular iron modulation. E2 has also been shown to inhibit the release of several cytokines including IL-1, IL-6, IL-22, TGF-β1, and TLR5, at least some of which (IL-1 and IL-6) are known to upregulate hepcidin synthesis [21]. By downregulating hepcidin synthesis and upregulating FPN expression, E2 treatment was recently reported to enhance labile intracellular iron efflux in MCF-7 and SKOV-3 cells [22] (Figure 2).

Infection, immunity and the fight for iron: Owing to its significant redox potential, iron availability is essential for both pathogen and host immunity. Iron enhances the growth and virulence of pathogens; at the same time, it is essential for the activation and proliferation of immune cells [23]. Therefore, iron deficiency negatively affects the pathogen and the host, albeit more so in the case of host immunity. This partially explains the well-documented observation that patients with iron deficiency exhibit increased susceptibility to infection. Iron overload also seems to favor the pathogen, as it tends to suppress host immunity [23]. At homeostatic conditions however, with the primary phase of microbial infections ensues a bitter fight for iron. Immune cells fight to sequester iron by upregulating the expression of IL-1 and IL-6 among other mediators that enhance hepcidin synthesis and block intracellular iron efflux [22]. By doing so, innate immunity deprives the pathogen of badly-needed iron and arrests its growth and dissemination [24]. To counter such an inflammation-dependent iron sequestration response, pathogense have evolved an exquisite ability to chelate iron from heme and other molecules by expressing ferric reductase [25] and iron-chelating siderophores and hemophores (e.g. desferrichrocin, desferrichrome, desferritubin, and desferrichrysin) [26]. Therefore, high-affinity iron scavenging by siderophores is a well-recognized virulence determinant in microbial pathogenesis in mammals [27]. High pathogenicity islands in pathogenic strains of Yersinia and several members of the enterobacteriaceae use the iron acquisition molecule yersiniabactin to chelate iron from host proteins [28]. Increased synthesis of proteins involved in iron-uptake and utilization has been documented in human blood cultures of methicillin-resistant Staphylococcus aureus [29]. Better protection against mucormycosis was achieved in immunocompromised hosts by using the non-siderophoric desferaloxin in place of the siderophoric iron chelator deferoxamine [30]. Susceptibility of liver transplant patients to invasive aspergillosis, cryptococcosis, and zygomycosis has been shown to correlate with iron overload [31]. Use of desferaloxin in conjunction with liposomal amphotericin B has also been shown to improve treatment outcome by increasing survival and reducing fungal burden in mice with invasive pulmonary aspergillosis (IPA) [30,32]. Proteomic analysis has shown that the expression of proteins involved in iron acquisition by the marine bacterium Vibrio vulnificus significantly increases during the early-middle growth phase of the pathogen [33]. Secreted glutathione-dependent ferric reductase activity in Histoplasma capsulatum was shown to aid in iron acquisition and sequestration and hence pathogenesis over a broad pH range [34].

Iron acquisition systems in pathogens not only help the pathogen to grow and become more virulent, but also suppress host immunity. Several gastrointestinal microbes have been reported to sequester iron from the host in order to disrupt the activity of phagocytes that require iron for the production of hydroxyl radicals and superoxide reactions as means of microbial killing [35]. Furthermore, siderophores like desferrioxamine (DFO), desferrichrome (DFC), desferrieroxbactin (DFAB) and desferrienterobactin (DFEBA) enhance the virulence of pathogens [36-38] by helping the pathogen acquire iron and induce immunosuppression in the host [37].

Notwithstanding the fact that iron is critical for immune cell proliferation and activation, iron overload resulting from dietary excess, abnormal hemolysis or inherited disorders often associates with immunosuppression and increased susceptibility to infection [39, 40-42]. The immunosuppressive effects of iron on immunity manifests in a whole host of innate and adaptive responses. In that, increased iron concentration in HepG2 cells infected with C. trachomatis show reduced indoleamine 2,3-dioxygenase (IDO; the enzyme that catalyses tryptophan metabolism) expression and diminished potential to inhibit the infection through IFN-γ [43]. Iron overload in liver transplant recipients has been reported to minimize the need for immunosuppressive therapy [44]. Upregulated expression of genes involved in iron metabolism, increased serum levels of hepcidin and ferritin, and hepatocyte iron deposition has been observed in such patients [44]. This suggests that endogenous iron may exert immunosuppressive effects at a level high enough to allow for graft survival without the need for immunosuppressive therapy. Iron-overloaded mice with experimental candidiasis fail to mount strong candidal reactions; neutrophils and macrophages in such mice show reduced ability to produce nitric oxide and IL-12 [45]. However, treatment with deferoxamine helps to resolve the infection, restore phagocytic function and re-direct Th differentiation from a non-protective (IL-4 producer) to a protective (IFN-γ producer) phenotype [45].

More on the relationship between iron and immunity

The identification of key genes involved in iron regulation and
homeostasis in various types of immune cells including T cells and macrophages has expanded our knowledge of the relationship between immunity and iron. Now, it is becoming clear that both iron and the immune response differentially and reciprocally interact with one another. That said, immunity plays a considerable role in managing intracellular iron and in responding measurably to changing levels of systemic iron. On the other hand, iron and iron regulatory proteins modulate the immune response at different levels and in different contexts. Several studies have shown that immune cells do participate in iron homeostasis in general. That said, much remains to be done to fully appreciate the extent of such interactions and their effects on the immune response and on iron homeostasis. This notwithstanding, the short discussion below is only meant to introduce the reader to this emerging area in immunological and iron biology research. Lactoferrin (an iron binding, transport and storage protein) exerts significant immune-regulatory effects on Th1/Th2 cell activities [46]. Transferrin in macrophages and T lymphocytes [47] has proven essential for early T-cell differentiation [48]. Transferrin receptor 1 (TIR1) has been shown to be critical for DNA synthesis and cell division in T lymphocytes [49]. Both macrophages and T lymphocytes have been shown to express significant levels of the iron storing protein ferritin (FT) [50-51]. Expression of Nramp1 (SCLA11) and Nramp2/DMT1 on late phagosome was reported to enhance resistance to intracellular pathogens [52-53]. The intracellular iron efflux protein FPN1 (FPNIREG1) was shown to downregulate during microbial infections in a TLR4-dependent manner [54]. Hemochromatosis (iron overload) was reported to often associate with disrupted hepcidin gene expression [55]; hepcidin is an antimicrobial peptide and a key regulator of iron homeostasis [56]. The ability of IL-1 and IL-6 to enhance hepcidin synthesis and downregulate FPN expression seems to be instrumental in depriving pathogens of badly-needed iron during infection [21,57]. Targeted disruption of heme-oxygenase 1 (Hmox1; the enzyme that neutralizes iron) in mice was reported to induce iron overload [58]; high CD4/CD8 ratios with activated CD4+ cells were documented in these mice. Lastly, MHC-class I deficient mice tend to develop hepatic iron overload [59] and show reduced protection against viral infections due to their inability to present viral peptides to host antigen presenting cells (APCs) [60].

**Competing Interests**

The authors declare that they have no competing interests.

**Authors Contributions**

MH wrote and edited the manuscript and designed figure 2, KB helped to assemble the required references, prepared figure 1, and reviewed the manuscript. Both authors have read and approved the final manuscript.

**Acknowledgments**

This work was supported by research grants (i) UOS-MH-15010505100-P, College of Graduate Studies and Research, University of Sharjah, Sharjah, UAE and (ii) AFJ2016-64, Al-Jalila Foundation, Dubai, UAE in addition to a research group operational budget, the Sharjah Institute for Medical Research, University of Sharjah, Sharjah, UAE.

**References**

1. Aziz N, Munro HN (1987) Iron regulates ferritin mRNA translation through a segment of its 5′ untranslated region. Proc Natl Acad Sci U S A 84: 8478-8482. [Crossref]
16. Yang Q, Juan J, Katz S, Abramson SB, Huang X (2012) 17β-Estradiol inhibits iron hormone hepcidin through an estrogen responsive element half-site. Endocrine 153: 3170-3178. [Crossref]
capsulatum secreted gamma-glutamyltransferase reduces iron by generating an efficient ferric reductant. Molecular Microbiology 70: 352-368. [Crossref]


36. Keqin Hua, Jingxin Dn, Qc Cao, Weivi Feng, Ying Zhang, et al. (2009) Estrogen and progesteron regulate HIF-1 expression in ovarian cancer cell lines via the activation of Akt signaling transduction pathway. *Oncology Reports* 21: 893-899. [Crossref]


40. Moyo VM, Garcia-Perez I, Gordeuk VR, Kiire CF, Macphail AP (1997) Tuberculosis and non-malignant lymphoid cells. *Br J Haematol* 93: 1011-1012. [Crossref]

41. Magnus SA, Hambleton IR, Moosdeen F, Serjeant GR (1999) Recurrent infections in homozygous sickle cell disease. *Arch Dis Child* 80: 537-541. [Crossref]


